Eyenovia, Inc. ( EYEN ) NASDAQ Capital Market

Cena: 15.82 ( 49.81% )

Aktualizacja 07-02 22:00
NASDAQ Capital Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 57
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 82%
Ilość akcji: 44 122 200
Debiut giełdowy: 2018-01-25
WWW: https://www.eyenovia.com
CEO: Mr. Michael M. Rowe
Adres: 295 Madison Avenue
Siedziba: 10017 New York
ISIN: US30234E1047
Opis firmy:

Eyenovia, Inc., firma okulistyczna sceniczna, angażuje się w opracowywanie terapeutyków w oparciu o jego zastrzeżoną technologię platformy platformy MICRODOSE BRATHRAY. Firma koncentruje się na opracowaniu klinicznego mikrodingu preparatów środków farmaceutycznych okulistycznych przy użyciu ukierunkowanego systemu dostarczania oka. Koncentruje się na rozwoju wskazań terapeutycznych u pacjentów z postępującą krótkowzrocznością i związanymi z wiekiem w pobliżu zaburzenia wzroku lub wskazaniach Presbyopia; i mikrodoza stała kombinacja farmaceutyka okulistycznego dla mydriasis w celu rozwiązania badań wzroku z rozszerzeniem źrenicy. Kandydaci na produkty firmy obejmują mikrolinę, która jest w programie rozwoju klinicznego fazy III ze wskazaniami do poprawy widzenia w pobliżu osób z presbyopią; Mikropine, która jest w programie rozwoju klinicznego fazy III ze wskazaniami do progresji krótkowzroczności pediatrycznej (bliskie prawość); i MyDcombi, który jest w programie rozwoju klinicznego fazy III ze wskazaniami farmaceutycznej mydriasis. Ma umowę licencyjną z Bausch Health Ireland Limited w celu opracowania i komercjalizacji mikropiny w Stanach Zjednoczonych i Kanadzie; oraz umowa licencyjna z Arctic Vision (Hongkong) ograniczona do opracowywania i komercjalizacji mikropin i mikroliny w Chinach i Korei Południowej. Firma była wcześniej znana jako PGP Holdings V, Inc. i zmieniła nazwę na Eyenovia, Inc. w maju 2014 r. Eyenovia, Inc. została zarejestrowana w 2014 roku i ma siedzibę w Nowym Jorku w Nowym Jorku.

Wskaźniki finansowe
Kapitalizacja (USD) 80 750 975
Aktywa: 22 796 091
Cena: 15.82
Wskaźnik Altman Z-Score: -15.8
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -0.4
Ilość akcji w obrocie: 82%
Średni wolumen: 4 652 726
Ilość akcji 5 104 360
Wskaźniki finansowe
Przychody TTM 31 832
Zobowiązania: 19 076 788
Przedział 52 tyg.: 0.85 - 124.8
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -42.6
P/E branży: 26.1
Beta: 1.755
Raport okresowy: 2025-08-11
WWW: https://www.eyenovia.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Michael M. Rowe Chief Executive Officer & Director 775 468 1962
Mr. John P. Gandolfo CPA Chief Financial Officer & Secretary 578 154 1961
Mr. Bren Kern Chief Operating Officer & Corporate Vice President 415 585 1981
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH Co-Founder & Executive Chairman 167 500 1974
Alexander Lobo Investor Contact 0 0
Wiadomości dla Eyenovia, Inc.
Tytuł Treść Źródło Aktualizacja Link
Eyenovia Provides Development Update on Optejet User Filled Device (UFD) On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 globenewswire.com 2025-04-10 11:00:00 Czytaj oryginał (ang.)
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol ® water-free drug delivery technology for glaucoma with Eyenovia's Optejet ® device platform globenewswire.com 2025-03-20 09:00:00 Czytaj oryginał (ang.)
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule. globenewswire.com 2025-02-26 09:00:00 Czytaj oryginał (ang.)
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs globenewswire.com 2025-02-24 09:00:00 Czytaj oryginał (ang.)
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization globenewswire.com 2025-02-05 09:00:00 Czytaj oryginał (ang.)
Eyenovia Announces 1-for-80 Reverse Stock Split Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives globenewswire.com 2025-01-28 18:05:00 Czytaj oryginał (ang.)
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th globenewswire.com 2025-01-15 09:00:00 Czytaj oryginał (ang.)
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% globenewswire.com 2025-01-06 09:00:00 Czytaj oryginał (ang.)
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”),  an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 40,170,050 shares of common stock in a registered direct offering at a combined offering price of $0.0969 per share and accompanying warrants. The warrants will have an exercise price of $0.0969 per share, will be exercisable commencing six months from the date of issuance or, if required by The Nasdaq Capital Market, upon receipt of approval of the Company's stockholders, and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about December 9, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com 2024-12-06 10:00:00 Czytaj oryginał (ang.)
Eyenovia Provides Update on Restructuring Efforts Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025 globenewswire.com 2024-11-22 09:00:00 Czytaj oryginał (ang.)
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee. zacks.com 2024-11-18 12:50:30 Czytaj oryginał (ang.)
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia. benzinga.com 2024-11-15 15:15:39 Czytaj oryginał (ang.)
Eyenovia to discontinue late-stage study for eye drug Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal. reuters.com 2024-11-15 09:07:51 Czytaj oryginał (ang.)
Eyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint globenewswire.com 2024-11-15 09:00:00 Czytaj oryginał (ang.)
Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Participants Matthew Caufield - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Lachlan Hanbury-Brown - William Blair Kemp Dolliver - Brookline Capital Markets Len Yaffe - Stoc Doc Partners Operator Greetings and welcome to Eyenovia's Third Quarter 2024 Earnings Call. seekingalpha.com 2024-11-13 00:42:42 Czytaj oryginał (ang.)
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.18 per share a year ago. zacks.com 2024-11-12 20:51:20 Czytaj oryginał (ang.)
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT globenewswire.com 2024-11-07 09:00:00 Czytaj oryginał (ang.)
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery globenewswire.com 2024-10-16 11:00:00 Czytaj oryginał (ang.)
Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now Eyenovia (EYEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com 2024-10-14 14:56:45 Czytaj oryginał (ang.)
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 globenewswire.com 2024-10-01 11:00:00 Czytaj oryginał (ang.)
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8,695,653 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,695,653 shares of common stock in a registered direct offering at a combined offering price of $0.46 per share and accompanying warrant. The warrants have an exercise price of $0.50 per share, will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about September 30, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com 2024-09-27 12:30:00 Czytaj oryginał (ang.)
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information globenewswire.com 2024-09-26 11:00:00 Czytaj oryginał (ang.)
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization TAIPEI , Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora Pharmaceuticals Ophthalmic (hereinafter referred to as "Bora," 6472.TW). prnewswire.com 2024-09-09 07:00:00 Czytaj oryginał (ang.)
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024 Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024 globenewswire.com 2024-09-05 11:00:00 Czytaj oryginał (ang.)
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition globenewswire.com 2024-09-03 11:00:00 Czytaj oryginał (ang.)
Eyenovia Announces Closing of Public Offering NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). globenewswire.com 2024-08-23 15:42:00 Czytaj oryginał (ang.)
Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday? Eyenovia Inc EYEN stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro. benzinga.com 2024-08-22 18:20:49 Czytaj oryginał (ang.)
Eyenovia Announces Pricing of $5.14 Million Public Offering NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). globenewswire.com 2024-08-21 13:29:00 Czytaj oryginał (ang.)